WallStSmart

Concord Medical Services Holdings (CCM)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 14355% more annual revenue ($66.57B vs $460.51M). MRK leads profitability with a 4.8% profit margin vs -20.2%. CCM appears more attractively valued with a PEG of 0.57. CCM earns a higher WallStSmart Score of 43/100 (D).

CCM

Hold

43

out of 100

Grade: D

Growth: 5.3Profit: 2.0Value: 7.7Quality: 5.5
Piotroski: 6/9Altman Z: -0.95

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CCMUndervalued (+67.5%)

Margin of Safety

+67.5%

Fair Value

$11.77

Current Price

$3.97

$7.80 discount

UndervaluedFair: $11.77Overvalued
MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$144.85

$62.01 premium

UndervaluedFair: $82.84Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCM3 strengths · Avg: 9.3/10
Revenue GrowthGrowth
57.4%10/10

Revenue surging 57.4% year-over-year

Debt/EquityHealth
-1.7310/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.578/10

Growing faster than its price suggests

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

CCM4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$17.24M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-21.9%2/10

ROE of -21.9% — below average capital efficiency

Altman Z-ScoreHealth
-0.952/10

Distress zone — elevated risk

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : CCM

The strongest argument for CCM centers on Revenue Growth, Debt/Equity, PEG Ratio. Revenue growth of 57.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bear Case : CCM

The primary concerns for CCM are EPS Growth, Market Cap, Return on Equity.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

CCM profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.

MRK carries more volatility with a beta of 0.23 — expect wider price swings.

CCM is growing revenue faster at 57.4% — sustainability is the question.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

CCM scores higher overall (43/100 vs 36/100) and 57.4% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Concord Medical Services Holdings

HEALTHCARE · MEDICAL CARE FACILITIES · China

Concord Medical Services Holdings Limited, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company is headquartered in Beijing, the People's Republic of China.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?